Treatment of Severe Swallowing Dysfunction in Systemic Sclerosis with IVIG: Role of Antimuscarinic Antibodies
Authors:
- Fabian A. MendozaFMFabian A. Mendoza
- Anthony DiMarinoADAnthony DiMarino
- Sidney CohenSCSidney Cohen
- Christopher AdkinsCAChristopher Adkins
- Shady AbdelbakiSAShady Abdelbaki
- Satish RattanSRSatish Rattan
- Christopher CaoCCChristopher Cao
- Susie Denuna-RiveraSDSusie Denuna-Rivera
- Sergio A. JimenezSJSergio A. Jimenez
Open Access
- 10 November 2022
- journal article
- case report
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 11 (22) , 6665
Abstract
Oropharyngeal and esophageal dysmotility can cause serious clinical complications such as aspiration pneumonia, cachexia, and sarcopenia, with a resulting increase in mortality and disability. The current standard of care for the treatment of SSc-associated swallowing dysfunction is mainly supportive, although severe cases are usually refractory to conventional management. Recent studies have shown that the abnormal production of functional autoantibodies such as anti-cholinergic muscarinic receptor III antibodies may participate in the pathogenesis of SSc-associated gastrointestinal dysmotility and may provide a novel target for therapeutic intervention. We describe two patients with severe and rapid onset of SSc-associated severe swallowing dysfunction and esophageal dysmotility who had failed standard of care therapy, requiring complete enteral and parenteral nutrition. Both patients were positive for the presence of circulating antimuscarinic III receptor antibodies. They were treated with IVIG at a dose of 2 g/Kg/month divided in two consecutive days, for six months. Following IVIG therapy, both patients markedly improved their symptoms as shown by a reduction in their UCLA2.0 score, and achieved an improvement of esophageal motility documented radiologically. Both patients resumed oral feeding and had their feeding tubes removed within the treatment period. None of the patients developed severe adverse events attributable to IVIG, except for low-grade fever during IVIG infusion in one of the cases. These results provide support for the role of functional autoantibodies in the development of SSc-associated gastrointestinal dysfunction.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (RO1DK035385)
This publication has 24 references indexed in Scilit:
- Role of muscarinic-3 receptor antibody in systemic sclerosis: correlation with disease duration and effects of IVIGAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2016
- Sustained benefit from intravenous immunoglobulin therapy for gastrointestinal involvement in systemic sclerosisRheumatology, 2015
- Intravenous immunogobulin therapy for severe gastrointestinal involvement in systemic sclerosis.2015
- Management of Gastrointestinal Involvement in SclerodermaCurrent Treatment Options in Rheumatology, 2015
- Immunotherapy trial as diagnostic test in evaluating patients with presumed autoimmune gastrointestinal dysmotilityNeurogastroenterology & Motility, 2014
- Effects of Scleroderma Antibodies and Pooled Human Immunoglobulin on Anal Sphincter and Colonic Smooth Muscle FunctionGastroenterology, 2012
- Gastrointestinal Manifestations of Scleroderma: Recent Progress in Evaluation, Pathogenesis, and ManagementCurrent Rheumatology Reports, 2011
- Muscarinic-3 acetylcholine receptor autoantibody in patients with systemic sclerosis: contribution to severe gastrointestinal tract dysmotilityAnnals of the Rheumatic Diseases, 2009
- Antiidiotypic antibodies neutralize autoantibodies that inhibit cholinergic neurotransmissionArthritis & Rheumatism, 2003
- Oropharyngeal and esophageal function in sclerodermaDysphagia, 1991